Vertex Prepares For HCV Combo Research By Licensing Two Compounds From Alios
This article was originally published in The Pink Sheet Daily
Executive Summary
Vertex pays $60 million upfront to license two nucleotide polymerase inhibitors it will test in combination therapy with other HCV assets in its pipeline.
You may also be interested in...
Pegasys Returns To Growth In U.S., But Few Other Reasons To Cheer In Roche's Nine-Month Results
Currency headwinds lead Roche to report a 13% decline in pharmaceutical sales in the first nine months of 2011, although at constant exchange rates, sales grew by 1%.
Pegasys Returns To Growth In U.S., But Few Other Reasons To Cheer In Roche's Nine-Month Results
Currency headwinds lead Roche to report a 13% decline in pharmaceutical sales in the first nine months of 2011, although at constant exchange rates, sales grew by 1%.
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2011
Of the $6.3 billion total raised, 32% was from China distributor Shanghai Pharmaceuticals' $1.99 billion IPO - not only Q2's biggest financing, but also the second-largest pharma IPO of all time. Six of the 26 completed mergers were done to gain access to emerging markets, most notably, Takeda's $13.7 billion buy of Nycomed, almost half of the total $27.9 billion spent on pharma acquisitions this quarter. Q2's largest alliance was Vertex's in-licensing of Alios BioPharma's preclinical HCV nucleotide analogues, a deal that could be worth up to $775 million in up fronts and development milestones.